Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an "anchor" drug?

Autoimmunity Reviews

Volumn 13, Issue 11, 2014, Pages 1102-1108

  Favalli, Ennio Giulio ^a   Biggioggero, Martina ^a,b   Meroni, Pier Luigi ^a,b  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; REVIEW; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; DRUG DESIGN; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; METHOTREXATE; TREATMENT OUTCOME;

EID: 84908546592     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.026     Document Type: Review

References (77)

1. Black C.M., O'Brien M., Vanscott E.J., Auerbach R., Eisen A.Z., Bunim J.J. Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 1964, 189:743-747.
2. Weinblatt M.E., Coblyn J.S., Fox D.A., Fraser P.A., Holdsworth D.E., Glass D.N., et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822.
3. Williams H.J., Willkens R.F., Samuelson C.O., Alarcón G.S., Guttadauria M., Yarboro C., et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985, 28:721-730.
4. Cutolo M., Sulli A., Craviotto C., Felli L., Pizzorni C., Seriolo B., et al. Antiproliferative-antiinflammatory effects of methotrexate and sex hormones on cultured differentiating myeloid monocytic cells (THP-1). Ann N Y Acad Sci 2002, 966:232-237.
5. Moreland L.W., Bridges S.L. Early rheumatoid arthritis: a medical emergency?. Am J Med 2001, 111:498-500.
6. Sokka T., Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002, 29:2521-2524.
7. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
8. Chighizola C.B., Favalli E.G., Meroni P.L. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol 2014, 47:6-16.
9. Linsley P.S., Nadler S.G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009, 229:307-321.
10. Caporali R., Bugatti S., Cavagna L., Antivalle M., Sarzi-Puttini P. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?. Autoimmun Rev 2014, 13:49-53.
11. Bugatti S., Codullo V., Caporali R., Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007, 7:137-142.
12. Dörner T., Radbruch A., Burmester G.R. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009, 5:433-441.
13. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542.
14. Klareskog L., van der Heijde D.M., de Jager J.P., Gough A., Kalden J.R., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
15. Lipsky P.E., van der Heijde D.M., Clair E.W.S., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000, 343:1594-1602.
16. Keystone E.C., Kavanaugh A., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
17. Keystone E.C., van der Heijde D.M., Mason D., Landewé R., van Vollenhoven R.F., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329.
18. Keystone E.C., Genovese M.C., Klareskog L., Hsia E.C., Hall S., Miranda P.C., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010, 69:1129-1135.
19. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
20. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
21. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
22. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
23. Marchesoni A., Zaccara E., Gorla R., Bazzani C., Sarzi-Puttini P., Atzeni F., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009, 1173:837-846.
24. Favalli E.G., Desiati F., Atzeni F., Sarzi-Puttini P., Caporali R., Pallavicini F.B., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:266-273.
25. Atzeni F., Sarzi-Puttini P., Mutti A., Bugatti S., Cavagna L., Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013, 12:1115-1117.
26. Wolfe F., Hawley D.J., Cathey M.A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990, 17:994-1002.
27. Riise T., Jacobsen B.K., Gran J.T. Changes in therapy of rheumatoid arthritis during the period 1979 to 1996. Scand J Rehabil Med 2001, 30:199-202.
28. Aletaha D., Smolen J.S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002, 41:1367-1374.
29. Weinblatt M.E., Kaplan H., Germain B.F., Merriman R.C., Solomon S.D., Wall B., et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990, 33:330-338.
30. Williams H.J., Ward J.R., Reading J.C., Brooks R.H., Clegg D.O., Skosey J.L., et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992, 35:259-269.
31. Jeurissen M.E., Boerbooms A.M., van de Putte L.B., Doesburg W.H., Mulder J., Rasker J.J., et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991, 34:961-972.
32. Jeurissen M.E., Boerbooms A.M., van de Putte L.B., Doesburg W.H., Lemmens A.M. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991, 114:999-1004.
33. Willkens R.F., Sharp J.T., Stablein D., Marks C., Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995, 38:1799-1806.
34. Drosos A.A., Voulgari P.V., Papadopoulos I.A., Politi E.N., Georgiou P.E., Zikou A.K. Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clin Exp Rheumatol 1998, 16:695-701.
35. Ferraccioli G.F., Gremese E., Tomietto P., Favret G., Damato R., Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002, 41:892-898.
36. Hamilton J., McInnes I.B., Thomson E.A., Porter D., Hunter J.A., Madhok R., et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001, 60:566-572.
37. Rau R., Herborn G., Menninger H., Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002, 41:196-204.
38. Strand V., Cohen S., Schiff M.H., Weaver A., Fleischmann R.M., Cannon G., et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999, 159:2542-2550.
39. Cohen S.B., Cannon G.W., Schiff M.H., Weaver A., Fox R.I., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001, 44:1984-1992.
40. Strand V., Scott D.L., Emery P., Kalden J.R., Smolen J.S., Cannon G.W., et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005, 32:590-601.
41. Emery P., Breedveld F.C., Lemmel E.M., Kaltwasser J.P., Dawes P.T., Gömör B., et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:655-665.
42. Bao C., Chen S., Gu Y., Lao Z., Ni L., Yu Q., et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J 2003, 116:1228-1234.
43. Haagsma C.J., van Riel P.L., de Jong A.J., van de Putte L.B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52week clinical trial. Br J Rheumatol 1997, 36:1082-1088.
44. Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999, 58:220-225.
45. Capell H.A., Madhok R., Porter D.R., Munro R.A.L., Mcinnes I.B., Hunter J.A., et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007, 66:235-241.
46. Pope J.E., Hong P., Koehler B.E. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 2002, 29:255-260.
47. Mielants H., Veys E.M., Van der Straeten C., Ackerman C., Goemaere S. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol 1991, 18:978-983.
48. Furst D.E., Koehnke R., Burmeister L.F., Kohler J., Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989, 16:313-320.
49. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E. Initiative 2009, 68:1086-1093.
50. Tugwell P., Pincus T., Yocum D., Stein M., Gluck O., Kraag G., et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995, 333:137-141.
51. Marchesoni A., Battafarano N., Arreghini M., Panni B., Gallazzi M., Tosi S. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 2003, 42:1545-1549.
52. Kremer J.M., Genovese M.C., Cannon G.W., Caldwell J.R., Cush J.J., Furst D.E., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137:726-733.
53. Lehman A.J., Esdaile J.M., Klinkhoff A.V., Grant E., Fitzgerald A., Canvin J., et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005, 52:1360-1370.
54. O'Dell J.R., Haire C.E., Erikson N., Drymalski W., Palmer W., Eckhoff P.J., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
55. Katchamart W., Trudeau J., Phumethum V., Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009, 68:1105-1112.
56. Gaujoux-Viala C., Smolen J.S., Landewé R., Dougados M., Kvien T.K., Mola E.M., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1004-1009.
57. de Jong P.H., Hazes J.M., Barendregt P.J., Huisman M., van Zeben D., van der Lubbe P.A., et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013, 72:72-78.
58. Moreland L.W., O'Dell J.R., Paulus H.E., Curtis J.R., Bathon J.M., St Clair E.W., et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012, 64:2824-2835.
59. Smolen J.S., Landewé R., Breedveld F.C., Buch M.H., Burmester G.R., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 3:492-509.
60. van der Heijde D.M., Klareskog L., Rodríguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074.
61. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2009, 69:88-96.
62. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
63. Breedveld F.C., Weisman M.H., Kavanaugh A., Cohen S.B., Pavelka K., van Vollenhoven R.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2005, 54:26-37.
64. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
65. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
66. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
67. Emery P., Fleischmann R.M., Moreland L.W., Hsia E.C., Strusberg I., Durez P., et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009, 60:2272-2283.
68. Tak P.P., Rigby W.F., Rubbert-Roth A., Peterfy C.G., van Vollenhoven R.F., Stohl W., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
69. Westhovens R., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009, 68:1870-1877.
70. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
71. Soubrier M., Puéchal X., Sibilia J., Mariette X., Meyer O., Combe B., et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009, 48:1429-1434.
72. Burmester G.R., Kivitz A.J., Kupper H., Arulmani U., Florentinus S., Goss S.L., et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2014 Feb 18, [Electronic publication ahead of print]. 10.1136/annrheumdis-2013-204769.
73. Dougados M., Kissel K., Sheeran T., Tak P.P., Conaghan P.G., Mola E.M., et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2012, 72:43-50.
74. Burmester G., Rigby W., van Vollenhoven R., Kay J., Rubbert-Roth A., Kelman A., et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis 2013, 72:OP041. (Suppl.).
75. Yazici Y., Shi N., John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008, 66:77-85.
76. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P.M., Silman A.J. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
77. Listing J., Strangfeld A., Rau R., Kekow J., Gromnica-Ihle E., Klopsch T., et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006, 8:R66.